Some of the findings from the current study question existing views on post opera tive seizure outcomes. For example, previous reports contend that occurrence of simple partial seizures (SPSz) in the immediate postoperative years has no impact on the longterm likelihood of seizure freedom. 9 Conversely, de Tisi et al. found that patients with postoperative SPSz were over 50% more likely to experience dys cognitive seizures in the long term than were those who were completely seizurefree in the first 2 years. Further more, indivi duals who were com pletely seizurefree after surgery were more likely to be free of dyscognitive seizures over time than those who experienced SPSz (89% versus 81% 2 years after surgery, 86% versus 67% at 5 years, and 78% versus 55% at 10 years).
Some methodological differences may explain the discrepancies between findings from previous studies and those of de Tisi and colleagues. Previous reports focused only on patients with auras-SPSz with sub jective symptoms and no outward clinical expression-whereas de Tisi et al. included individuals with any SPSz that did not impair the patient's awareness. Also, previous studies included only patients who had auras before surgery to enable direct comparison with auras in the post operative period; the de Tisi et al. study did not have this require ment. Finally, the method of identifying sei zures may have differed between the studies. Whether differences in methodology explain the dissent remains unclear, but an existing notion has clearly been questioned and will require further exploration.
Researchers have previously found that the duration of an initial remission is related to the chance of future seizure freedom. 10 In the new study, de Tisi et al. fully investigated this idea by performing annual analyses of seizure remission and relapse over a median of 8 years.
7 They found that seizure remis sion or relapse in any given year was the best indicator of seizure freedom in the follow ing year, and the longer a person remained seizurefree the lower the chance of future recurrence. Importantly, the opposite was also true: the longer a person continued to have seizures, the lower the chance of ever achieving seizure remission. However, a small proportion of patients who had epi lepsy for many years achieved freedom from seizures through use of new AEDs.
One of the most interesting aspects of the current study was the characterization of different patterns of seizure remission and relapse following surgery, and the fre quency with which each pattern occurred in the cohort. 7 The patterns included sus tained seizure freedom, which occurred in half of the patients, persistent seizures (the second most common outcome), and other pat terns of remission and relapse (Figure 1 ). These observations highlight two important methodological limitations in the published evidence on epilepsy surgery. First, the study shows that the time frame in which research ers have reported seizure freedom is inade quate: 90% of reports have focused on seizure freedom in the last year or 'at last followup' without further specification, and about 10% of published studies did not specify a time frame for follow up, or did not clearly define the time frame.
3 Second, the study by de Tisi and colleagues underscores the difficulties that researchers face in providing meaning ful analyses of seizure outcomes. The shifting patterns of remission and relapse exhibited by onethird of patients following surgery for epilepsy cannot be captured by an overall estimate of percent decrease in seizures, sur vival analyses (such as Kaplan-Meier analy ses) of time to the n th seizure, or a snapshot of seizure occurrence during the past year.
Unpredictable paroxysms with remissions and recurrences that unfold over time typify the outcomes in most patients with epi lepsy. The analysis by de Tisi et al. provides a cogent picture of the response to epilepsy surgery in individual patients, and shows that postoperative outcomes are not static, but dynamic, and often capricious. Recognizing the possibility of different outcome patterns after epilepsy surgery will be important to help clinicians and patients make sense of the complexity of outcomes, and to adjust their expectations accordingly. Intensive glucose management can, how ever, cause frequent bouts of severe hypo glyce mia, such that any vascular benefit from this intervention could, theoretically, be off set by hypoglycemiainduced im pairments, in cluding cognitive decline.
Longterm (~18 years) followup of inten sively treated, relatively young patients with type 1 diabetes found no adverse cogni tive effects, and indicated that poor glyce mic control might promote mild cognitive deterior ation, 4 but less is known about cog nitive outcomes in patients with type 2 dia betes under intensive glucose management. Because this older patient population exhib its mild deficits in memory and information processing compared with agematched nondiabetic controls, efforts to prevent cognitive decline are especially important.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial assessed whether aggressive glucose lowering to a target glycated hemoglobin (Hb A1c ) level of <6.0% of total hemoglobin versus stan dard therapy (Hb A1c 7.0-7.9%) can improve cardio vascular outcomes in elderly patients with longstanding diabetes who are at high risk of cardiovascular complications.
5
Within ACCORD, the Memory in Diabetes (MIND) study was a randomized, openlabel substudy that aimed to determine whether restoration of normoglycemia in type 2 dia betes influences cognitive performance or agerelated brain atrophy.
6
Of the 2,977 patients enrolled in the MIND substudy, 1,378 participants com pleted the intensive intervention and 1,416 completed the standard interven tion. Characteristics of the participants and changes in blood glucose levels were repre sentative of those in the parent ACCORD trial. The primary outcome, cognitive performance, was measured using a Digit Symbol Substitution Test (DSST) at base line and at 20 and 40 months after enroll ment. Total brain volume was measured using MRIbased morphometry in a smaller subset of patients before and 40 months after initiation of treatment.
An unexpected increase in cardiovascu lar events and mortality in the intensive glucosecontrol arm of ACCORD after a mean followup period of 3.5 years led to discontinuation of the trial.
5 Despite the early termination, most of the indivi duals enrolled in ACCORDMIND had almost completed the predetermined goal of 40 months of followup, and the results of this substudy have recently been reported by Launer and colleagues. 6 Although the study provided evidence of preserved brain volume following intensive glucose lower ing, no statistically significant differ ence between the groups with regard to the primary end point, cognitive perfor mance, was found. The authors concluded that intensive glucose lowering should not be undertaken to delay cognitive impair ment in elderly patients with longstanding type 2 diabetes. Do these findings mean that the question as to whether intensive management pre vents cognitive deficits is, once and for all, off the table? Our response would be "not quite yet." Several important factors could have influenced the negative study outcome, and careful inspection of the data reveals clues to suggest that followup questions should be addressed in subsequent studies.
Hypoglycemia in the intensivetreatment group probably had the most profound influence on the MIND results. Assuming that the frequency distribution of hypo glycemic events in the MIND cohort was similar to that seen in the ACCORD cohort (episodes requiring medical assis tance in the intensivetreatment versus the standardtreatment arms were 4.28 versus 1.37 per 100 personyears), the exposure to hypoglycemia must have been consider able.
7 Although patients with a prior history of severe hypoglycemia were explicitly excluded from the MIND study, the occur rence of hypoglycemia during the trial was not factored into Launer and colleagues' mixedmodel analysis. 6 In addition to diabetes per se, 1 hypo glycemia in type 2 diabetes has recently been identified as an additional risk factor for development of dementia.
8 From our own work we know that exposure to recurrent hypoglycemia, on the one hand, and expo sure to prolonged hyperglycemia, on the other, leads to adaptations in brain metabo lism, some of which are protective, whereas others are maladaptive. 9 The aggressive g lucoselowering regimen in MIND might have led to acute brain injury from severe hypoglycemia in some patients that offset the benefits conferred by reduced exposure to hyperglycemia in other patients. The coexistence of preserved brain volume and higher prevalence of abnormal white matter lesions on MRI in the intensivetreatment arm than in the standardtreatment arm may attest to this fact. Furthermore, to achieve normo glycemia, patients in the intensive treatment arm were generally given mul tiple oral agents, often in conjunction with insulin. The poly pharmacy approach, rather than insulin alone, might thereby have had adverse effects in addition to hypoglycemia.
Another confounding factor, which was only revealed in a followup ACCORD MIND analysis, was the association between micro vascular renal complications and poor cognitive performance. As diabetic nephro pathy was not included in the initial mixed model adjustments of the MIND study, a separate analysis of results from this group of patients-who were at a high risk of cognitive decline 10 and might benefit from the elimination of chronic hy perglycemia -could not be conducted.
The specific study population itself could also have obscured differences between intensive and conventional therapy groups. Given the age and health status of the patients involved, the damage to brain struc tures may have already occurred at the time the trial commenced, thereby mak ing an effect of glucoselowering treat ment on cognitive capacity difficult to show. Consistent with this possibility, a sub group analysis (albeit underpowered to show statistical significance) indicated a positive trend towards preserved cogni tive function in intensively treated patients who were newly diagnosed or <60 years of age. Impor tance of intervention at a young age is also consistent with the failure to show benefit of aggressive treatment on cardiovas cular outcomes in ACCORD. Finally, the study duration may simply have been too short to allow significant cognitive differences to develop between the study arms, a possibility that is supported by the detection of preserved brain volume in the in tensivetreatment group.
Future studies should certainly include longterm followup of the cohort from the MIND study, which will allow us to determine whether aggressive normaliza tion of plasma glucose for a relatively short time has an impact on longterm cognitive decline and is protective against dementia. In the meantime, we believe that patients with advanced complications, such as those in the ACCORDMIND study, would benefit from lesscomplex drug regimens '' Several important factors could have influenced the negative study outcome...
''
www.nature.com/nrneurol NEWS & VIEWS and a glycemic target that improves-but does not attempt to entirely normalize -plasma glucose levels. Intensive glucose management is considerably more likely to be effective earlier in the course of type 2 diabetes, at a time when glucose control is easier to achieve and vascular complications and cognitive changes are less advanced. These assumptions will need to be directly tested in future longterm prospective studies to improve the clinical management of cognitive decline in type 2 diabetes.
